Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100716 | 0.87 | L3MBTL1 (0.52) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL23674985 | 0.87 | L3MBTL1 (0.52) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL26086688 | 0.84 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL16163267 | 0.81 | L3MBTL1 (0.53) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL30100711 | 0.81 | L3MBTL1 (0.53) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL16163258 | 0.79 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL14938439 | 0.74 | MEN1 (0.71) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL5988304 | 0.74 | PTGDR2 (0.43) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL30100692 | 0.73 | POLB (0.71) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL30100689 | 0.73 | POLB (0.71) | L3MBTL1MEN1KMT2ACASP3APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622874-B1 | 3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070105845-A1 | Quinolone derivatives | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105845-A1 | Quinolone derivatives | NQO2, NQO1, RECQL | L3MBTL1 4674/4885MEN1 694/4885KMT2A 2950/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | L3MBTL1 2442/4885MEN1 2755/4885KMT2A 647/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | L3MBTL1 186/4885MEN1 4612/4885KMT2A 565/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | L3MBTL1 3451/4885MEN1 2243/4885KMT2A 2954/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | L3MBTL1 3499/4885MEN1 237/4885KMT2A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.